NCT01427946View on ClinicalTrials.gov

Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

October 31, 2014

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

IPI-504

DRUG

Everolimus

Trial Locations (5)

10017

Memorial Sloan Kettering Cancer Center, New York

33612

Moffitt Cancer Center, Tampa

80045

University of Colorado Denver, Aurora

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Infinity Pharmaceuticals, Inc.

INDUSTRY

NCT01427946 - Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter